HDLs, immunity, and atherosclerosis

Current Opinion in Lipidology

Volumn 22, Issue 5, 2011, Pages 410-416

  Norata, Giuseppe D ^a,b   Pirillo, Angela ^b,c   Catapano, Alberico L ^a,c  

^a UNIVERSITY OF MILAN   (Italy)

^b Ospedale Bassini   (Italy)

^c IRCCS MULTIMEDICA   (Italy)

Author keywords

apoA I; high density lipoprotein; immune response; sphingosine 1 phosphate

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN;

ANTIGEN PRESENTING CELL; ATHEROGENESIS; ATHEROSCLEROSIS; B LYMPHOCYTE; HUMAN; IMMUNITY; LIVER; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL; HUMANS; INFLAMMATION; LIPOPROTEINS, HDL;

EID: 80052752534     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32834adac3     Document Type: Review

References (77)

1. Von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001; 21:13-27. (Pubitemid 32061923)
2. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364:127-135.
3. Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by highdensity lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol 2003; 23:1724-1731. (Pubitemid 37254854)
4. Lusis AJ. Atherosclerosis. Nature 2000; 407:233-241.
5. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340:115-126.
6. Oram JF. ATP-binding cassette transporter A1 and cholesterol trafficking. Curr Opin Lipidol 2002; 13:373-381. (Pubitemid 34831940)
7. Wang X, Collins HL, Ranalletta M, et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest 2007; 117:2216-2224. (Pubitemid 47219566)
8. Moudry R, Spycher MO, Doran JE. Reconstituted high density lipoprotein modulates adherence of polymorphonuclear leukocytes to human endothelial cells. Shock 1997; 7:175-181. (Pubitemid 127654265)
9. Bensinger SJ, Bradley MN, Joseph SB, et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 2008; 134:97-111. (Pubitemid 351905740)
10. Wilhelm AJ, Zabalawi M, Grayson JM, et al. Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity. Arterioscler Thromb Vasc Biol 2009; 29:843-849.
11. Landry YD, Denis M, Nandi S, et al. ATP-binding cassette transporter A1 expression disrupts raft membrane microdomains through its ATPase-related functions. J Biol Chem 2006; 281:36091-36101. (Pubitemid 46041342)
12. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997; 387:569-572. (Pubitemid 27248754)
13. Brown DA, London E. Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 1998; 14:111-136. (Pubitemid 29001451)
14. McIntosh TJ, Vidal A, Simon SA. Sorting of lipids and transmembrane peptides between detergent-soluble bilayers and detergent-resistant rafts. Biophys J 2003; 85:1656-1666. (Pubitemid 37052248)
15. Kabouridis PS, Janzen J, Magee AL, Ley SC. Cholesterol depletion disrupts lipid rafts and modulates the activity of multiple signaling pathways in T lymphocytes. Eur J Immunol 2000; 30:954-963. (Pubitemid 30216271)
16. Anderson HA, Hiltbold EM, Roche PA. Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation. Nat Immunol 2000; 1:156-162.
17. Jury EC, Flores-Borja F, Kabouridis PS. Lipid rafts in T cell signalling and disease. Semin Cell Dev Biol 2007; 18:608-615. (Pubitemid 350026426)
18. Kabouridis PS. Lipid rafts in T cell receptor signalling. Mol Membr Biol 2006; 23:49-57.
19. Zeyda M, Stulnig TM. Lipid Rafts & Co.: an integrated model of membrane organization in T cell activation. Prog Lipid Res 2006; 45: 187-202.
20. Hiltbold EM, Poloso NJ, Roche PA.MHC class II-peptide complexes and APC lipid rafts accumulate at the immunological synapse. J Immunol 2003; 170:1329-1338. (Pubitemid 36139500)
21. Poloso NJ, Roche PA. Association of MHC class II-peptide complexes with plasma membrane lipid microdomains. Curr Opin Immunol 2004; 16:103-107. (Pubitemid 38202217)
22. Setterblad N, Roucard C, Bocaccio C, et al. Composition of MHC class IIenriched lipid microdomains is modified during maturation of primary dendritic cells. J Leukoc Biol 2003; 74:40-48. (Pubitemid 38040435)
23. Eren E, Yates J, Cwynarski K, et al. Location of major histocompatibility complex class II molecules in rafts on dendritic cells enhances the efficiency of T-cell activation and proliferation. Scand J Immunol 2006; 63:7-16.
24. Zilber MT, Setterblad N, Vasselon T, et al. MHC class II/CD38/CD9: a lipidraft-dependent signaling complex in human monocytes. Blood 2005; 106: 3074-3081. (Pubitemid 41565903)
25. Murphy AJ, Woollard KJ, Hoang A, et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol 2008; 28:2071-2077.
26. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21:1876-1890. (Pubitemid 34219736)
27. Bobryshev YV, Lord RS. Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions. Cardiovasc Res 1998; 37:799-810. (Pubitemid 28231176)
28. Strunk D, Rappersberger K, Egger C, et al. Generation of human dendritic cells/Langerhans cells from circulating CD34\+ hematopoietic progenitor cells. Blood 1996; 87:1292-1302. (Pubitemid 26056892)
29. Zhou LJ, Tedder TF. CD14\+ blood monocytes can differentiate into functionally mature CD83\+ dendritic cells. Proc Natl Acad Sci USA 1996; 93:2588-2592. (Pubitemid 26104391)
30. Kim KD, Lim HY, Lee HG, et al. Apolipoprotein A-I induces IL-10 and PGE2 production in human monocytes and inhibits dendritic cell differentiation and maturation. Biochem Biophys Res Commun 2005; 338:1126-1136. (Pubitemid 41597754)
31. Matzinger P. Friendly and dangerous signals: is the tissue in control? Nat Immunol 2007; 8:11-13. (Pubitemid 46242350)
32. Niessner A, Weyand CM. Dendritic cells in atherosclerotic disease. Clin Immunol 2010; 134:25-32.
33. Dopheide JF, Sester U, Schlitt A, et al. Monocyte-derived dendritic cells of patients with coronary artery disease show an increased expression of costimulatory molecules CD40, CD80 and CD86 in vitro. Coron Artery Dis 2007; 18:523-531. (Pubitemid 47556383)
34. O'Neill LA. 'Fine tuning' TLR signaling. Nat Immunol 2008; 9:459-461.
35. Erridge C. The roles of Toll-like receptors in atherosclerosis. J Innate Immun 2009; 1:340-349.
36. Cole JE, Georgiou E, Monaco C. The expression and functions of toll-like receptors in atherosclerosis. Mediators Inflamm 2010; 2010:393946.
37. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002; 105:1158-1161. (Pubitemid 34225814)
38. Xu XH, Shah PK, Faure E, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001; 104:3103-3108. (Pubitemid 34014065)
39. Triantafilou M, Miyake K, Golenbock DT, Triantafilou K. Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J Cell Sci 2002; 115:2603-2611. (Pubitemid 34778077)
40. Smythies LE, White CR, Maheshwari A, et al. Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophages. Am J Physiol Cell Physiol 2010; 298:C1538-C1548.
41. Bjorkbacka H, Fitzgerald KA, Huet F, et al. The induction of macrophage gene expression by LPS predominantly utilizes Myd88-independent signaling cascades. Physiol Genomics 2004; 19:319-330. (Pubitemid 40039937)
42. Le Page C, Genin P, Baines MG, Hiscott J. Interferon activation and innate immunity. Rev Immunogenet 2000; 2:374-386. (Pubitemid 32041163)
43. Suzuki M, Pritchard DK, Becker L, et al. High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide. Circulation 2010; 122: 1919-1927.
44. Van Lenten BJ, Wagner AC, Nayak DP, et al. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation 2001; 103:2283-2288. (Pubitemid 32433719)
45. Van Lenten BJ, Wagner AC, Anantharamaiah GM, et al. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation 2002; 106:1127-1132. (Pubitemid 34970855)
46. Hyka N, Dayer JM, Modoux C, et al. Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contactmediated activation of monocytes by T lymphocytes. Blood 2001; 97:2381-2389. (Pubitemid 32291485)
47. Van Lenten BJ, Wagner AC, Navab M, et al. D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation 2004; 110:3252-3258. (Pubitemid 39525074)
48. Dykstra M, Cherukuri A, Sohn HW, et al. Location is everything: lipid rafts and immune cell signaling. Annu Rev Immunol 2003; 21:457-481. (Pubitemid 37174538)
49. Gupta N, DeFranco AL. Lipid rafts and B cell signaling. Semin Cell Dev Biol 2007; 18:616-626. (Pubitemid 350026423)
50. Kabouridis PS, Jury EC. Lipid rafts and T-lymphocyte function: implications for autoimmunity. FEBS Lett 2008; 582:3711-3718.
51. Pappu R, Schwab SR, Cornelissen I, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 2007; 316:295-298. (Pubitemid 46633109)
52. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296:346-349. (Pubitemid 34303689)
53. Liu G, Yang K, Burns S, et al. The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and T(reg) cells. Nat Immunol 2010; 11:1047-1056.
54. Scanu AM, Edelstein C. HDL: bridging past and present with a look at the future. FASEB J 2008; 22:4044-4054.
55. Nofer JR, Bot M, Brodde M, et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007; 115:501-508. (Pubitemid 46188244)
56. Keul P, Tolle M, Lucke S, et al. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27:607-613.
57. Blom T, Back N, Mutka AL, et al. FTY720 stimulates 27-hydroxycholesterol production and confers atheroprotective effects in human primary macrophages. Circ Res 2010; 106:720-729.
58. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427:355-360. (Pubitemid 38133663)
59. Ammirati E, Cianflone D, Banfi M, et al. Circulating CD4\+CD25hiCD127lo regulatory T-cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30:1832-1841.
60. Wilhelm AJ, Zabalawi M, Owen JS, et al. Apolipoprotein A-I modulates regulatory T cells in autoimmune LDLr-/-, ApoA-I-/-mice. J Biol Chem 2010; 285:36158-36169.
61. Yvan-Charvet L, Pagler T, Gautier EL, et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 2010; 328: 1689-1693.
62. Coetzee GA, Strachan AF, van der Westhuyzen DR, et al. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem 1986; 261:9644-9651. (Pubitemid 17214087)
63. Van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96:2758-2767.
64. Stonik JA, Remaley AT, Demosky SJ, et al. Serum amyloid A promotes ABCA1-dependent and ABCA1-independent lipid efflux from cells. Biochem Biophys Res Commun 2004; 321:936-941. (Pubitemid 39044399)
65. Kisilevsky R, Tam SP. Macrophage cholesterol efflux and the active domains of serum amyloid A 2.1. J Lipid Res 2003; 44:2257-2269. (Pubitemid 38082484)
66. Van der Westhuyzen DR, Cai L, de Beer MC, de Beer FC. Serum amyloid A promotes cholesterol efflux mediated by scavenger receptor B-I. J Biol Chem 2005; 280:35890-35895. (Pubitemid 41633856)
67. Cai L, de Beer MC, de Beer FC, van der Westhuyzen DR. Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake. J Biol Chem 2005; 280:2954-2961. (Pubitemid 40189405)
68. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007; 117:746-756. (Pubitemid 46348533)
69. Rezaee F, Casetta B, Levels JH, et al. Proteomic analysis of high-density lipoprotein. Proteomics 2006; 6:721-730. (Pubitemid 43208050)
70. Heinecke JW. The HDL proteome: a marker-and perhaps mediator-of coronary artery disease. J Lipid Res 2009; 50 (Suppl.):S167-S171.
71. Rosenfeld SI, Packman CH, Leddy JP. Inhibition of the lytic action of cellbound terminal complement components by human high density lipoproteins and apoproteins. J Clin Invest 1983; 71:795-808. (Pubitemid 13163251)
72. Hamilton KK, Zhao J, Sims PJ. Interaction between apolipoproteins A-I and A-II and the membrane attack complex of complement. Affinity of the apoproteins for polymeric C9. J Biol Chem 1993; 268:3632-3638. (Pubitemid 23071007)
73. Pasqui AL, Puccetti L, Bova G, et al. Relationship between serum complement and different lipid disorders. Clin Exp Med 2002; 2:33-38. (Pubitemid 34743945)
74. Norata GD, Marchesi P, Pirillo A, et al. Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol 2008; 28:925-931. (Pubitemid 351544109)
75. Deban L, Russo RC, Sironi M, et al. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol 2010; 11:328-334.
76. Norata GD, Garlanda C, Catapano AL. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med 2010; 20:35-40.
77. Norata GD, Marchesi P, Pulakazhi Venu VK, et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 2009; 120:699-708.